GRAIL has been named on Fortune’s 2023 Change the World List.
Now in its 9th year, Fortune’s Change the World list features companies addressing society’s biggest challenges – those who have had a positive social impact through activities that are part of their core business. Companies are assessed on factors including measurable social impact, business results and innovation.
GRAIL is being recognized for its work to transform care across the cancer continuum and change the trajectory of cancer mortality. GRAIL’s Galleri® multi-cancer early detection (MCED) test is a first-of-its-kind screening test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal. GRAIL believes the transformative power of MCED is realized when the Galleri test detects and localizes a shared cancer signal, providing physicians with valuable information to guide diagnostic testing.
“Being included on Fortune’s Change the World List is an honor that recognizes our dedication to GRAIL’s mission – to detect cancer early, when it can be cured – and the work of everyone at GRAIL to meaningfully make a difference in cancer,” said Bob Ragusa, chief executive officer at GRAIL. Our goal is to redefine the status quo of cancer detection and our teams continue to work together to bring about the public health change needed to dramatically improve cancer outcomes.”
To compile the list, FORTUNE selected companies that made the greatest contributions to society this year, beyond just profitability. See the full list here.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission.
For more information, visit grail.com.
The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect a shared cancer signal across more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, with high accuracy to help guide the next steps to diagnosis. The Galleri test requires a prescription from a licensed health care provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or older.
For more information about Galleri, visit galleri.com.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.